🎀 Fight.Cure.Win • Patient Guide
Treatment & Options
Quick map of common first-line and standard options by cancer type. Actual plans depend on stage, tumor biology, overall health, and personal preferences. Always discuss your choices with your oncology team.
| Cancer Type | Local/First-Line Options | Systemic / Targeted / Immunotherapy | Learn More |
|---|---|---|---|
| Breast (Invasive) ER/PR/HER2 subtypes |
Lumpectomy + RT
Mastectomy ± recon
Sentinel node
|
Endocrine (ER+)
Anti-HER2 (HER2+)
Chemo
Immunotherapy (TNBC select)
CDK4/6, PARP (select)
|
NCI: Breast |
| Prostate Risk-stratified |
Active surveillance (low)
Prostatectomy
External RT / Brachy
|
ADT (hormone)
AR inhibitors
Chemo (mHSPC/mCRPC)
Radioligand (select)
|
NCI: Prostate |
| Lung — NSCLC Early vs metastatic |
Surgery (early)
SBRT (inoperable)
Chemo-RT (locally adv.)
|
Targeted (EGFR/ALK/ROS1/BRAF/KRAS-G12C…)
Immunotherapy (PD-1/PD-L1)
Chemo ± IO
|
NCI: Lung |
| Lung — SCLC |
Chemo-RT (limited)
RT to chest (select)
|
Chemo + IO (extensive)
PCI (select)
|
NCI: SCLC |
| Colorectal (Colon & Rectal) |
Polypectomy (early)
Colectomy / TME
Chemo-RT (rectal)
Metastasis surgery/ablation (select)
|
Chemo (FOLFOX/FOLFIRI)
Anti-VEGF
Anti-EGFR (RAS WT, left-sided)
Immunotherapy (MSI-H/dMMR)
|
NCI: Colorectal |
| Pancreatic (Exocrine) |
Surgery (Whipple/distal)
Neoadj/Adjuvant chemo
|
FOLFIRINOX
Gemcitabine ± nab-paclitaxel
Targeted/IO (select biomarkers)
|
NCI: Pancreatic |
| Gastric (Stomach) |
Peri-op chemo + Gastrectomy
RT (select)
|
Chemo
Anti-HER2 (HER2+)
Immunotherapy (PD-L1 select)
|
NCI: Stomach |
| Liver — Hepatocellular (HCC) |
Resection/Transplant
Ablation
TACE/TARE
|
IO + Anti-VEGF (e.g., atezo/bev)
TKIs (sorafenib/lenvatinib, etc.)
|
NCI: Liver |
| Bile Duct (Cholangiocarcinoma) |
Resection (select)
Biliary drainage/stent
Adjuvant therapy (select)
|
Gem/Cis ± IO
FGFR/IDH1 targeted (select)
|
NCI: Bile Duct |
| Esophageal |
Neoadj chemoradiation + Surgery
Definitive chemoradiation
|
Chemo ± IO
Anti-HER2 (subset)
|
NCI: Esophageal |
| Head & Neck (incl. HPV+) |
Surgery (select sites)
Chemoradiation
Reconstruction/rehab
|
ChemoImmunotherapy
|
NCI: Head & Neck |
| Cervical |
Conization (very early)Radical hysterectomyChemoradiation + Brachy
|
ChemoImmunotherapyAnti-VEGF (select)
|
NCI: Cervical |
| Endometrial (Uterine) |
Hysterectomy ± nodesRadiation (select)
|
Hormonal (select)ChemoImmunotherapy (dMMR/MSI-H)
|
NCI: Uterine |
| Ovarian / Fallopian / Primary Peritoneal |
Cytoreductive surgeryPlatinum-based chemo
|
PARP inhibitors (BRCA/HRD)Bevacizumab (select)
|
NCI: Ovarian |
| Bladder NMIBC vs MIBC |
TURBT
Intravesical BCG (NMIBC)
Cystectomy (MIBC)
|
Chemo (cisplatin-based)ImmunotherapyADC (select)
|
NCI: Bladder |
| Kidney (Renal Cell) |
Partial/Radical nephrectomy
|
IO + TKI combosTKI monotherapy
|
NCI: Kidney |
| Melanoma (Skin) |
Wide excisionSentinel node (select)
|
ImmunotherapyBRAF/MEK (BRAF+)Adjuvant therapy (select)
|
NCI: Melanoma |
| Skin — Basal & Squamous Cell |
ExcisionMohs surgeryTopicals/PDT (superficial)
|
Hedgehog inhibitors (adv BCC)PD-1 inhibitors (adv cSCC)
|
NCI: Skin |
| Brain — Glioblastoma |
Maximal safe resectionRadiation + Temozolomide
|
TTFieldsTrials/targeted (select)
|
NCI: Brain |
| Lymphoma — DLBCL |
Chemo-immunotherapy (R-CHOP)RT (select)
|
Polatuzumab combosCAR T (relapsed)
|
NCI: Lymphoma |
| Lymphoma — Follicular |
Observation (low burden)RT (localized)
|
Rituximab ± chemoTargeted/IO (select)CAR T (relapsed)
|
NCI: Lymphoma |
| Leukemia — AML |
Induction + ConsolidationTransplant (select)
|
FLT3/IDH inhibitorsVenetoclax combos
|
NCI: AML |
| Leukemia — ALL |
Multi-phase chemoCNS prophylaxis
|
TKI (Ph+)Bi-specifics/ADCCAR T (select)Transplant (risk-based)
|
NCI: ALL |
| Leukemia — CLL/SLL |
Watch & wait (asymptomatic)
|
BTK inhibitorsVenetoclax + anti-CD20
|
NCI: CLL |
| Leukemia — CML | — |
TKIs (imatinib & newer)TFR in select
|
NCI: CML |
| Multiple Myeloma |
Triplet/Quad inductionASCT (eligible)Maintenance
|
Proteasome/IMiD/anti-CD38CAR T / Bi-specifics (relapsed)
|
NCI: Myeloma |
| Soft Tissue Sarcoma |
Surgery (wide margins)RT (adj/neoadj)
|
Chemo (subtype-dependent)Targeted (e.g., GIST TKIs)
|
NCI: Sarcoma |
| Thyroid |
ThyroidectomyRadioactive iodine (DF)
|
TSH suppressionTargeted (RAI-refractory/medullary)
|
NCI: Thyroid |
| Testicular (Germ Cell) |
OrchiectomySurveillance/RT (seminoma, select)RPLND (select)
|
Chemo (BEP/EP)
|
NCI: Testicular |
| Wilms Tumor (Pediatric) |
NephrectomyRT (select)
|
Chemo (risk-adapted) |
NCI: Wilms |
Sources: National Cancer Institute treatment overviews for each cancer type (linked above). This table is educational and not medical advice.